BioCentury This Week

BioCentury This Week

Por: BioCentury
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
332 episodios disponibles

Latest episodes of the podcast BioCentury This Week

Mostrando página 7 de 17

Ep. 205 - Radiotherapy Deep Dive; Plus: Congress, BioNTech 27/11/2023
Ep. 204 - First CRISPR Approval & IRA’s Lost Orphans 20/11/2023
Ep. 203 - POC for Verve? Plus: IRA & East-West Deals 13/11/2023
Ep. 202 - A DMD Decision & Endpoint Innovation 06/11/2023
Ep. 201 - ESMO, NIH & IRA 30/10/2023
Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors 23/10/2023
Ep. 199 - China Summit Preview 20/10/2023
Ep. 198 - Novartis Finds Focus & EU Pharma Law 16/10/2023
Ep. 197 - Mirati Takeout & 4Q23 Financial Markets Preview 09/10/2023
Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi 02/10/2023
Ep. 195 - East-West Summit Preview 25/09/2023
Ep. 194 - IPO Outlook & IRA Lawsuits 18/09/2023
Ep. 193 - East-West CAR T Deals, Plus: Amgen-FTC 11/09/2023
Ep. 192 - Tier-jumpers: a Back to School Overview 05/09/2023
Ep. 191 - Circular RNA, Psychedelics, & Upcoming BioCentury Summits 21/08/2023
Ep. 190 - Obesity Mechanisms, Noubar Takeaways, Scleroderma Platform Trial 14/08/2023
Ep. 189 - Biogen-Sage Setback, Biotech IPOs, Sanofi Digital 07/08/2023
Ep. 188 – Pharma deals; Plus: Genentech, Leerink Conversations 31/07/2023
Ep. 187 - Alnylam-Roche; Plus: Insights on the IRA, FTC 24/07/2023
Ep. 186 - 3Q Markets Preview, Donanemab & Lilly-Versanis 17/07/2023
« Primera ‹ Anterior 1 ... 5 6 7 8 9 ... 17 Siguiente › Última »
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA